Work

PARPs in liver diseases

Year: 2025

Type: article

Abstract: Poly(ADP-ribose) polymerases (PARPs) comprise a family of 17 enzymes were initially identified for their essential roles in DNA damage repair and maintenance of genomic stability. Emerging evidence has unveiled their critical involvement in various liver diseases, including viral hepatitis, metabolic disorders, fibrosis, and hepatocellular carcinoma. This review summarizes PARPs’ roles in liver diseases and the evidence supporting PARP inhibitor therapy.

Source: npj gut and liver.

DOI: 10.1038/s44355-025-00043-x

Authors: Jiaxin Xia, Xiao Tang, Qihua Zhu, Yizhu Xu

Institutions: China Pharmaceutical University, State Key Laboratory of Natural Medicine, Nanjing University of Chinese Medicine

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,790